
‘Trump slump' blamed as fewer tourists visit Las Vegas
The iconic city, famed for its lavish entertainment and round-the-clock gambling, saw just under 3.1 million tourists in June, marking an 11 per cent decrease compared to the same time in 2024.
Data from the Las Vegas Convention and Visitors Authority further reveals a 13 per cent reduction in international travellers and a roughly 15 per cent fall in hotel occupancy.
Mayor Shelley Berkley highlighted the drastic drop in visitors from Canada, Nevada 's largest international market, describing the flow as having diminished "to a drip" from a torrent.
She noted a similar trend with Mexico, stating: "We have a number of very high rollers that come in from Mexico that aren't so keen on coming in right now. And that seems to be the prevailing attitude internationally."
Ted Pappageorge, who leads the influential Culinary Workers Union, has dubbed the situation the "Trump slump".
He also pointed to a decline in visits from Southern California, a region with a substantial Latino population, suggesting that fears surrounding the administration's immigration enforcement are deterring travel.
'If you tell the rest of the world they're not welcome, then they won't come,' Pappageorge said.
Canadian airline data shows fewer passengers from north of the border are arriving at Harry Reid International Airport in Las Vegas.
Air Canada saw its passenger numbers fall by 33 per cent in June compared to the same time a year ago, while WestJet had a 31 per cent drop. The low-cost carrier Flair reported a whopping 62 per cent decline.
Travel agents in Canada said there's been a significant downturn in clients wanting to visit the US overall, and Las Vegas in particular. Wendy Hart, who books trips from Windsor, Ontario, said the reason was 'politics, for sure.'
She speculated that it was a point of 'national pride' that people were staying away from the US after President Donald Trump said he wanted to make Canada the 51st state.
'The tariffs are a big thing too. They seem to be contributing to the rising cost of everything,' Hart said.
At downtown's Circa Resort and Casino, international visits have dipped, especially from Canada and Japan, according to owner and CEO Derek Stevens.
But the downturn comes after a post-COVID spike, Stevens said. And while hotel room bookings are slack, gaming numbers, especially for sports betting, are still strong, he said.
'It's not as if the sky is falling,' he said. Wealthier visitors are still coming, he said, and Circa has introduced cheaper package deals to lure those with less money to spend.
'There have been many stories written about how the 'end is near' in Vegas,' he said. 'But Vegas continues to reinvent itself as a destination worth visiting.'
On AAA 's annual top ten list of top Labor Day destinations, Las Vegas slipped this year to the last spot, from number six in 2024. Seattle and Orlando, Florida — home to Disneyworld — hold steady in the top two spots, with New York City moving up to third for 2025.
Reports of declining tourism were news to Alison Ferry, who arrived from Donegal, Ireland, to find big crowds at casinos and the Vegas Strip.
'It's very busy. It has been busy everywhere that we've gone. And really, really hot,' Ferry said. She added that she doesn't pay much attention to U.S. politics.
Just off the strip, there's been no slowdown at the Pinball Museum, which showcases games from the 1930s through today. Manager Jim Arnold said the two-decade-old attraction is recession-proof because it's one of the few places to offer free parking and free admission.
'We've decided that our plan is just to ignore inflation and pretend it doesn't exist," Arnold said.
'So you still take a quarter out of your pocket and put it in a game, and you don't pay a resort fee or a cancelation fee or any of that jazz.'
But Arnold said he's not surprised that overall tourism might be slowing because of skyrocketing prices at high-end restaurants and resorts, which 'squeezes out the low end tourist.'
The mayor said the rising cost of food, hotel rooms and attractions also keeps visitors away.
' People are feeling that they're getting nickeled and dimed, and they're not getting value for their dollar,' Berkley said. She called on business owners to 'see if we can't make it more affordable' for tourists.
'And that's all we want. We want them to come and have good time, spend their money, go home,' the mayor said. 'Then come back in six months.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
29 minutes ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.


Reuters
30 minutes ago
- Reuters
Utility Black Hills to buy peer NorthWestern Energy for $3.6 billion
Aug 19 (Reuters) - Utility company Black Hills (BKH.N), opens new tab said on Tuesday it would buy peer NorthWestern Energy (NWE.O), opens new tab for $3.6 billion, creating a larger regulated utility with greater scale to invest in grid infrastructure and meet rising energy demand. Consolidation in the U.S. power sector has boomed, propelled by the projections of record electricity demand over the next two years amid rapid expansion of energy-intensive AI and cryptocurrency data centers, along with increased residential and commercial consumption. The all-stock deal implies a per-share value of about $59, a premium of 7.66% to NorthWestern's last close, according to Reuters calculation. Shares of Black Hills rose 1.5% in volatile premarket trading. "Together, we will be better positioned to meet rising demand, accelerate investment in energy and grid infrastructure, and support customers and communities through a rapidly evolving energy landscape," said NorthWestern Energy CEO Brian Bird. The deal will create a regional electric and natural gas utility company with a pro forma market value of about $7.8 billion and a combined enterprise value of $15.4 billion. NorthWestern shareholders will receive 0.98 shares of Black Hills for each held. Black Hills stockholders would own roughly 56% of the company after the deal closes, which is expected in 12 to 15 months. The combined company will have a new name and ticker symbol and headquarters in Rapid City, South Dakota. Bird would continue to lead the combined company as CEO, while NorthWestern's current finance chief Crystal Lail would be the chief financial officer. The new company's board would comprise five directors designated by NorthWestern and six by Black Hills. Linn Evans, CEO of Black Hills, would retire once the transaction is completed.


Reuters
an hour ago
- Reuters
Budweiser maker Anheuser-Busch to invest $15 million in US brewery
Aug 19 (Reuters) - Anheuser-Busch InBev ( opens new tab, said on Tuesday that it would invest $15 million in its U.S. brewery, at a time when President Donald Trump is pushing to boost domestic production. This move is part of Anheuser-Busch's $300 million investment announced in May to create and sustain manufacturing jobs in the U.S. this year. Several businesses across the globe have been ramping up investments and expanding their presence in the United States to avoid tariffs and align with the Trump administration's "Made in America" push. AB InBev said the investment includes funding for supply chain infrastructure to transport its domestically grown ingredients to the St. Louis, Missouri brewery, and to get beer brands, including Budweiser and Bud Light, to consumers. In July, the company saw a decline in sales volumes due to tepid demand in Brazil and China, adding to investor woes over the industry growth.